

PRODUCT INFORMATION



BXL-628

Item No. 23129

CAS Registry No.: 199798-84-0

Formal Name: (1R,3Z,5S)-3-[(2E)-2-[(3aS,7aS)-1-[(1S,3E)-5-ethyl-5-hydroxy-1-methyl-3-hepten-1-yl]-3,3a,5,6,7,7a-hexahydro-7a-methyl-4H-inden-4-ylidene]ethylidene]-5-fluoro-4-methylene-cyclohexanol

Synonyms: Elocalcitol, Ro 26-9228

MF: $C_{29}H_{43}FO_2$

FW: 442.7


Purity: $\geq 98\%$

UV/Vis.: λ_{max} : 244, 269 nm

Supplied as: A crystalline solid

Storage: $-20^{\circ}C$

Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BXL-628 is supplied as a crystalline solid. A stock solution may be made by dissolving the BXL-628 in the solvent of choice, which should be purged with an inert gas. BXL-628 is soluble in organic solvents such as ethanol and DMSO. The solubility of BXL-628 in these solvents is approximately 20 and 30 mg/ml, respectively.

Description

BXL-628 is an analog of vitamin D₃ (Item No. 11792) that has diverse biological activities.¹⁻³ It increases death of androgen-stimulated human benign prostatic hyperplasia (BPH) cells *via* induction of apoptosis in a dose-dependent manner.¹ *In vivo*, BXL-628 completely inhibits androgen-stimulated prostate overgrowth in a rat model of BPH. It reduces expression of IL-13 and IgE/mast cell-derived protease 1 (MMCP1) and decreases edema and leukocyte infiltration in the bladder wall in a mouse model of allergen-induced interstitial cystitis.² BXL-628 also reduces the number of adherent endometrial stromal cells and decreases the total weight of endometrial lesions in a mouse model of endometriosis.³

References

1. Crescioli, C., Ferruzzi, P., Caporali, A., *et al.* Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. *Eur. J. Endocrinol.* **150**(4), 591-603 (2004).
2. Benigni, F., Baroni, E., Zecevic, M., *et al.* Oral treatment with a vitamin D₃ analogue (BXL628) has anti-inflammatory effects in rodent model of interstitial cystitis. *BJU Int.* **97**(3), 617-624 (2006).
3. Mariani, M., Viganò, P., Gentilini, D., *et al.* The selective vitamin D receptor agonist, elocalcitol, reduces endometriosis development in a mouse model by inhibiting peritoneal inflammation. *Hum. Reprod.* **27**(7), 2010-2019 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/16/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM